Key Points
- CFO David Barter sold 12,134 Cellebrite DI shares at an average price of $11.21, generating approximately $136,022. He retained 322,085 shares, reducing his position by 3.63%.
- Cellebrite shares opened at $11.15, with a $2.78 billion market capitalization and a one-year trading range of $9.58 to $19.98. Institutional investors own approximately 45.88% of the company.
- Analysts maintain a consensus “Moderate Buy” rating with a $16.70 price target, although several firms recently lowered their targets; five analysts rate the stock Buy and one rates it Sell.
Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CFO David Barter sold 12,134 shares of the business's stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $11.21, for a total value of $136,022.14. Following the completion of the transaction, the chief financial officer owned 322,085 shares in the company, valued at approximately $3,610,572.85. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Cellebrite DI Stock Performance
Shares of CLBT opened at $11.15 on Tuesday. The company has a market capitalization of $2.78 billion, a P/E ratio of 50.68, a P/E/G ratio of 1.69 and a beta of 1.14. Cellebrite DI Ltd. has a one year low of $9.58 and a one year high of $19.98. The stock has a 50-day moving average price of $11.53 and a 200 day moving average price of $13.08.
Hedge Funds Weigh In On Cellebrite DI
Large investors have recently modified their holdings of the stock. Elevation Wealth Partners LLC grew its stake in Cellebrite DI by 93.3% in the third quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company's stock worth $66,000 after purchasing an additional 2,816 shares in the last quarter. Tidal Investments LLC increased its holdings in Cellebrite DI by 12.5% in the second quarter. Tidal Investments LLC now owns 114,506 shares of the company's stock valued at $1,672,000 after buying an additional 12,749 shares during the last quarter. Nine Ten Capital Management LLC raised its stake in Cellebrite DI by 19.8% during the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company's stock valued at $60,251,000 after buying an additional 682,933 shares in the last quarter. Light Street Capital Management LLC raised its stake in Cellebrite DI by 104.8% during the second quarter. Light Street Capital Management LLC now owns 1,312,755 shares of the company's stock valued at $19,166,000 after buying an additional 671,830 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Cellebrite DI by 93.7% during the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company's stock valued at $44,529,000 after buying an additional 1,475,579 shares in the last quarter. Institutional investors own 45.88% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on CLBT shares. Lake Street Capital cut their target price on Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, August 14th. Needham & Company LLC decreased their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. DA Davidson reissued a "buy" rating and set a $15.00 price target on shares of Cellebrite DI in a research report on Tuesday, September 15th. Weiss Ratings lowered shares of Cellebrite DI from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 27th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating for the company in a research note on Friday, August 14th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.70.
Check Out Our Latest Analysis on CLBT
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI Ltd. is a digital intelligence company that develops technology for collecting, managing and analyzing digital evidence. Its solutions are designed to help law enforcement agencies, public safety organizations, government bodies and enterprises investigate activity involving mobile devices, computers, cloud services and other digital sources.
The company's product portfolio includes tools for mobile-device extraction and digital forensics, investigative analytics, evidence management and collaboration.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
